Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo.
作者信息
Shah Neil D, Fried Michael W
机构信息
Del UNC Liver Center University of North Carolina at Chapel Hill Chapel Hill NC, EE. UU.
出版信息
Clin Liver Dis (Hoboken). 2016 Nov 10;8(Suppl 1):S25-S29. doi: 10.1002/cld.594. eCollection 2016 Nov.
Abstract
摘要
相似文献
1
Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo.
Clin Liver Dis (Hoboken). 2016 Nov 10;8(Suppl 1):S25-S29. doi: 10.1002/cld.594. eCollection 2016 Nov.
2
Diverticular Colovaginal Fistulas: What Factors Contribute to Successful Surgical Management?
Dis Colon Rectum. 2019 Sep;62(9):1079-1084. doi: 10.1097/DCR.0000000000001445.
3
Importancia del "diagnóstico temprano" en los niños con cáncer para mejorar el pronóstico: concepto con poco sustento científico.
Gac Med Mex. 2018;154(4):520-526. doi: 10.24875/GMM.18004004.
4
Ligation of the Intersphincteric Fistula Tract for High Transsphincteric Fistula Yields Moderate Results at Best: Is the Tide Turning?
Dis Colon Rectum. 2019 Oct;62(10):1231-1237. doi: 10.1097/DCR.0000000000001448.
5
Implementation of a Postoperative Screening and Treatment Guidance for the Low Anterior Resection Syndrome: Preliminary Results.
Dis Colon Rectum. 2019 Sep;62(9):1033-1042. doi: 10.1097/DCR.0000000000001428.
6
Hemorrhoid Banding: A Cost-Effectiveness Analysis.
Dis Colon Rectum. 2019 Sep;62(9):1085-1094. doi: 10.1097/DCR.0000000000001444.
7
Mental Health Symptoms in Patients With Familial Adenomatous Polyposis: An Observational Study.
Dis Colon Rectum. 2019 Oct;62(10):1204-1211. doi: 10.1097/DCR.0000000000001459.
8
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
Dis Colon Rectum. 2019 Oct;62(10):1195-1203. doi: 10.1097/DCR.0000000000001456.
9
Guideline-Recommended Chemoradiation for Patients With Rectal Cancer at Large Hospitals: A Trend in the Right Direction.
Dis Colon Rectum. 2019 Oct;62(10):1186-1194. doi: 10.1097/DCR.0000000000001452.
10
[Not Available].
Nutr Hosp. 2016 Jul 19;33(4):387. doi: 10.20960/nh.387.
本文引用的文献
1
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.
2
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
J Hepatol. 2016 Feb;64(2):486-504. doi: 10.1016/j.jhep.2015.09.011. Epub 2015 Sep 26.
3
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
Hepatology. 2015 Sep;62(3):932-54. doi: 10.1002/hep.27950. Epub 2015 Aug 4.
4
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Antimicrob Agents Chemother. 2015 Sep;59(9):5445-54. doi: 10.1128/AAC.00998-15. Epub 2015 Jun 22.
5
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
J Hepatol. 2015 Sep;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. Epub 2015 Apr 18.
6
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Hepatology. 2015 Jun;61(6):1793-7. doi: 10.1002/hep.27814. Epub 2015 Apr 27.
7
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. Epub 2015 Mar 31.
8
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
J Viral Hepat. 2015 Nov;22(11):871-81. doi: 10.1111/jvh.12405. Epub 2015 Mar 18.
9
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10.
10
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.
Zotero 插件